Polynovo Ltd
Company Profile
Business description
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
Contact
320 Lorimer Street
Unit 2
Port MelbourneVIC3207
AUST: +61 386814050
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2026
Employees
8
Polynovo Ltd News & Analysis
stocks
ASX healthcare stocks shrug off new tariff threat
stocks
The ASX’s most shorted stocks
stocks
Will CEO departure upend ASX healthcare leader?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,030.90 | 39.90 | -0.44% |
CAC 40 | 7,854.61 | 67.63 | 0.87% |
DAX 40 | 23,674.53 | 315.35 | 1.35% |
Dow JONES (US) | 46,142.42 | 124.10 | 0.27% |
FTSE 100 | 9,228.11 | 19.74 | 0.21% |
HKSE | 26,544.85 | 363.54 | -1.35% |
NASDAQ | 22,470.72 | 209.40 | 0.94% |
Nikkei 225 | 45,303.43 | 513.05 | 1.15% |
NZX 50 Index | 13,120.03 | 108.35 | -0.82% |
S&P 500 | 6,631.96 | 31.61 | 0.48% |
S&P/ASX 200 | 8,745.20 | 47.70 | -0.54% |
SSE Composite Index | 3,831.66 | 44.68 | -1.15% |